Ireland's Amryt Aiming For Success Stateside

Files For NASDAQ Listing

With two revenue-generating products already on the market and Phase III data pending on Filsuvez for epidermolysis bullosa, CEO Joe Wiley has told Scrip that a US listing will give Amryt more visibility and credibility when it comes to future licensing and acquisition possibilities.

New York
Nasdaq listing will raise the visibility of Amryt • Source: Shutterstock

With its share price nudging 52-week highs and the integration of recently acquired Aegerion Pharmaceuticals Inc. going well, Ireland's Amryt Pharma PLC is now finalizing plans to list on the NASDAQ stock exchange.

Amryt, which is currently listed on London's AIM market and the Irish Stock Exchange's Euronext, has filed an application with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip